Humanigen to Present and Participate at Multiple Investor Ev

Humanigen, Inc. , a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that management will... | February 25, 2022

Related Keywords

New York , United States , Switzerland , London , City Of , United Kingdom , Adrian Kilcoyne , Cameron Durrant , Bob Atwill , Timothy Morris , Dale Chappell , Twitter , Humanigen Inc , Credit Suisse , Facebook , Nasdaq , Global Healthcare , Chief Scientific Officer , New York City , Annual Roth , Dana Point , Annual Healthcare , Europe Spring , Asia Pacific Region , Invest Pharmaceutical , Biotechnology Investor , Host Disease , Humanigen , Nc Stock Exchange , News , Information , Press Release , Iopharmaceutical , Company , Ocused , N , Preventing , End , Reating , Immune , Alled , Nnounced , Oday , Hat , Anagement Hgen Us4448632038 ,